Protagonist Therapeutics Inc (PTGX)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 279,408 | -78,955 | -127,393 | -125,551 | -64,845 |
| Revenue | US$ in thousands | 434,433 | 60,000 | 26,581 | 27,357 | 28,628 |
| Pretax margin | 64.32% | -131.59% | -479.26% | -458.94% | -226.51% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $279,408K ÷ $434,433K
= 64.32%
Protagonist Therapeutics Inc's pretax margin has exhibited significant fluctuations over the past five years. The company's pretax margin was severely negative in 2020 at -226.51%, further deteriorating to -458.94% in 2021, and dropping even lower to -479.26% in 2022. This trend suggests that the company was experiencing substantial losses relative to its revenue during these periods.
However, there seems to have been a notable turnaround in 2023, as the pretax margin improved to -131.59%, indicating some stabilization in the company's financial performance. Notably, in 2024, Protagonist Therapeutics Inc achieved a positive pretax margin of 64.32%, signaling a significant improvement in profitability.
Overall, the company has shown a mix of challenges and successes in managing its operating expenses relative to its revenue over the years. It is important for stakeholders to closely monitor future financial reports to assess the sustainability of this positive trend in profitability.
Peer comparison
Dec 31, 2024